PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Shanghai Fochon Pharmaceutical Co., Ltd.

USPTO PatentsView assignee record - 13 granted patents across 3 technology areas, recorded in grant years 2015–2021. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Shanghai ranks #21,748 of 50,000 tracked US assignees by granted-patent volume, with 13 patents across 3 technology areas.

#21,748
of 50,000 US assignees by volume
Top 87%
by Innovation Score (24.0/100)
14.6
avg claims per patent
-56%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R21748 · Foreign Corporation #21,748 · 13 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

  • GRANTS-MICRO 13 grants
  • MID-PACK #21,748/50,000
  • PHOTO-FINISH Server Products
  • CPC-NARROW A61P · 3 areas
  • INNOV-THIN 24.0/100
  • CLAIMS-RICH 14.6 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-DROP -56% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Server Products, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Shanghai

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Shanghai's Innovation Score is 24.0/100 (top 87% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Shanghai's grants concentrate

Shanghai Fochon Pharmaceutical Co., Ltd. is a focused PatentsView assignee: 3 CPC subclasses with 100% of grants classified under A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). Peak complete grant year is 2017 (3 grants) versus a trough of 1 in 2015. By volume, Shanghai sits between Server Products, Inc. and Shenzhen Dikai Industrial Co., Ltd..

Who files at Shanghai's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Shanghai holds 13 patents at rank #21,806, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Shanghai

By rank, the assignees closest to #21,806 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Shanghai's primary technology class.

Shanghai's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

24 Top 87% higher than 13% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). This entry sits in this band. 30–40: 15,294 US assignees (31%). Above this entry. 40–50: 11,491 US assignees (23%). Above this entry. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.533.5 201520172018201920202021 2
USPTO utility patent grants by year · 2015–2021

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Shanghai Fochon Pharmaceutical Co., Ltd. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 1 7.7%
2017 3 23.1%
2018 3 23.1%
2019 2 15.4%
2020 2 15.4%
2021 2 15.4%

Which technologies does Shanghai Fochon Pharmaceutical Co., Ltd. patent most?

Top 3 of 3 technology areas

Where it ranks

Overall rank by patents

#21,748

of 50,000 tracked assignees

Innovation Score

24.0 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?
Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.